metformin has been researched along with flutamide in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (52.63) | 29.6817 |
| 2010's | 24 (42.11) | 24.3611 |
| 2020's | 3 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C | 1 |
| de Zegher, F; Ibáñez, L | 7 |
| Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K | 1 |
| Cacciari, M; Gambineri, A; Genghini, S; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Pelusi, C | 1 |
| Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM | 1 |
| Kelestimur, F; Sahin, Y | 1 |
| Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P | 1 |
| Cabré, S; De Zegher, F; Ibáñez, L; Valls, C | 1 |
| Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C | 1 |
| Al-Inany, H | 2 |
| de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, AM | 1 |
| de Zegher, F; Ibáñez, L; Valls, C | 1 |
| de Zegher, F; Dunger, DB; Ibáñez, L | 1 |
| Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A | 1 |
| de Zegher, F; del Rio, L; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C | 1 |
| Conway, GS; Koulouri, O | 1 |
| de Zegher, F; Dunger, DB; Ibáñez, L; López-Bermejo, A; Ong, KK | 2 |
| de Zegher, F; Díaz, M; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C | 1 |
| de Zegher, F; del Río, L; Díaz, M; Enríquez, G; Ibáñez, L; López-Bermejo, A | 2 |
| Cahill, D | 1 |
| Brill, DS; Moenter, SM | 1 |
| de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A | 1 |
| Cabré, A; Díaz, M; Ibáñez, L; Lázaro, I; Masana, L | 1 |
| de Zegher, F; Diaz, M; Ibáñez, L; Lopez-Bermejo, A; Salvador, C; Sánchez-Infantes, D; Sebastiani, G | 1 |
| Beltran, A; Bladé, C; Correig, X; Díaz, M; Ibañez, L; Mallol, R; Rodriguez, MA; Samino, S; Vinaixa, M; Yanes, O | 1 |
| Chacón, MR; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Maymó-Masip, E; Salvador, C; Vendrell, J | 1 |
| Domecq, JP; Ehrmann, D; Erwin, PJ; Montori, VM; Mullan, RJ; Murad, MH; Prutsky, G; Sundaresh, V; Wang, AT; Welt, C | 1 |
| Buzney, C; Buzney, E; Reynolds, RV; Sheu, J | 1 |
| Carter, B; Fedorowicz, Z; Pandis, N; van Zuuren, EJ | 1 |
| Abi Salloum, B; Beckett, E; Herkimer, C; Moeller, J; Padmanabhan, V; Sreedharan, R; Veiga-Lopez, A | 1 |
| Casson, P; Hurliman, A; Keller Brown, J; Maille, N; Mandala, M; Osol, G | 1 |
| Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L | 1 |
| de Zegher, F; Díaz, M; Gallego-Escuredo, JM; Ibáñez, L; Villarroya, F | 1 |
| Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R | 1 |
| Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N | 1 |
| Esmaeilnezhad, S; Ghasemian, F | 1 |
| Hsiao, JL; Jeong, C; Masson, R; Shi, VY; Shih, T | 1 |
13 review(s) available for metformin and flutamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Medical treatment regimens of hirsutism.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Enzyme Inhibitors; Ethinyl Estradiol; Female; Finasteride; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Mineralocorticoid Receptor Antagonists; Spironolactone | 2004 |
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Progestins | 2004 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome; Spironolactone | 2004 |
Polycystic ovary syndrome.
Topics: Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; Humans; Metformin; Polycystic Ovary Syndrome; Spironolactone | 2005 |
A systematic review of commonly used medical treatments for hirsutism in women.
Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination; Female; Finasteride; Flutamide; Hirsutism; Humans; Metformin; Spironolactone; Thiazolidinediones; Treatment Outcome | 2008 |
PCOS.
Topics: Diabetes Mellitus, Type 2; Flutamide; Hair Removal; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome; Weight Loss | 2009 |
Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Contraceptives, Oral; Evidence-Based Medicine; Female; Flutamide; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Risk Factors; Venous Thromboembolism | 2013 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, Combined; Dermatology; Female; Finasteride; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Life Style; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spironolactone; Thiazolidinediones | 2014 |
Interventions for hirsutism (excluding laser and photoepilation therapy alone).
Topics: 5-alpha Reductase Inhibitors; Adult; Androgen Antagonists; Body Mass Index; Contraceptive Agents, Female; Cyproterone Acetate; Desogestrel; Drug Combinations; Eflornithine; Ethinyl Estradiol; Female; Finasteride; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Quality of Life; Randomized Controlled Trials as Topic; Spironolactone | 2015 |
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; Female; Flutamide; Humans; Hypoglycemic Agents; Life Style; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Research Design; Spironolactone; Systematic Reviews as Topic; Thiazolidinediones; Young Adult | 2015 |
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.
Topics: Androgens; Dexamethasone; Female; Flutamide; Humans; Hyperandrogenism; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Testosterone | 2023 |
Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review.
Topics: Finasteride; Flutamide; Hidradenitis Suppurativa; Humans; Liraglutide; Metformin; Spironolactone | 2023 |
24 trial(s) available for metformin and flutamide
| Article | Year |
|---|---|
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin | 2002 |
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hyperlipidemias; Metformin; Polycystic Ovary Syndrome; Sex Hormone-Binding Globulin | 2003 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Pilot Projects; Polycystic Ovary Syndrome; Random Allocation; Treatment Outcome | 2003 |
Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Contraceptive Agents, Female; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Metformin; Ovarian Diseases | 2003 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug Therapy, Combination; Female; Flutamide; Humans; Hypoglycemic Agents; Metformin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; Single-Blind Method | 2004 |
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Androstenes; Drug Therapy, Combination; Estrogens; Ethinyl Estradiol; Female; Flutamide; Hormone Antagonists; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Interleukin-6; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Proteins | 2004 |
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Estrogens; Ethinyl Estradiol; Female; Flutamide; Humans; Hypoglycemic Agents; Metformin; Norpregnenes; Obesity; Polycystic Ovary Syndrome | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; Humans; Hyperandrogenism; Intercellular Signaling Peptides and Proteins; Interleukin-6; Lipolysis; Metformin; Polycystic Ovary Syndrome; Proteins | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; Humans; Hyperandrogenism; Lipolysis; Metformin; Polycystic Ovary Syndrome; Time Factors | 2005 |
Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Flutamide; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Prospective Studies; Testosterone | 2004 |
High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception.
Topics: Adolescent; Adult; Androgen Antagonists; Child; Contraceptives, Oral; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Leukocyte Count; Menarche; Metformin; Neutrophils | 2005 |
Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.
Topics: Administration, Cutaneous; Adolescent; Adult; C-Reactive Protein; Contraceptive Agents, Female; Contraceptives, Oral; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Leukocyte Count; Lymphocytes; Metformin; Neutrophils; Tumor Necrosis Factor-alpha | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; Gonadal Steroid Hormones; Humans; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Prospective Studies; Sex Hormone-Binding Globulin | 2006 |
Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Topics: Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Body Mass Index; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Female; Flutamide; Glucose Tolerance Test; Hormones; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Lipids; Metformin; Pioglitazone; Thiazolidinediones; Ultrasonography | 2007 |
Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype.
Topics: Adolescent; Age Factors; Child; Cross-Over Studies; Drug Therapy, Combination; Female; Flutamide; Genotype; Humans; Hyperandrogenism; Menarche; Metformin; Ovarian Diseases; Receptors, Androgen | 2007 |
Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Topics: Adiponectin; Adolescent; Adult; Double-Blind Method; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Metformin; Nicotinamide Phosphoribosyltransferase; Pioglitazone; Thiazolidinediones; Young Adult | 2008 |
Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
Topics: Adolescent; Androgen Antagonists; Androgens; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Pilot Projects; Pioglitazone; Progestins; Thiazolidinediones; Young Adult | 2009 |
Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.
Topics: Adolescent; Alanine Transaminase; Androgens; Androstenes; Aspartate Aminotransferases; Blood Glucose; Body Composition; C-Reactive Protein; Cholesterol; Cross-Over Studies; Drug Therapy, Combination; Ethinyl Estradiol; Female; Flutamide; gamma-Glutamyltransferase; Humans; Hydro-Lyases; Insulin; Longitudinal Studies; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones; Tunica Intima; Young Adult | 2010 |
Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess.
Topics: Adolescent; Androgen Antagonists; Androstenes; Body Composition; Contraceptives, Oral, Hormonal; Ethinyl Estradiol; Female; Flutamide; Follistatin; Humans; Hyperandrogenism; Hyperinsulinism; Metformin; Young Adult | 2011 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined; Fatty Acid-Binding Proteins; Female; Flutamide; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Predictive Value of Tests; Puberty, Precocious; Treatment Outcome | 2011 |
Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Body Composition; Cyproterone Acetate; Drug Combinations; Estrogens; Ethinyl Estradiol; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Topics: Abdominal Fat; Biomarkers; Carotid Intima-Media Thickness; Chromatography, Gas; Chromatography, Liquid; Dicarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Health; Humans; Linoleic Acid; Lipoproteins; Magnetic Resonance Spectroscopy; Metabolomics; Metformin; Multivariate Analysis; Oxidation-Reduction; Pioglitazone; Polycystic Ovary Syndrome; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones; Young Adult | 2011 |
Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Angiopoietin-Like Protein 4; Angiopoietins; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Body Composition; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug Combinations; Ethinyl Estradiol; Female; Flutamide; Gene Expression; Humans; Hyperandrogenism; Hypoglycemic Agents; Leptin; Metformin; Pioglitazone; Receptors, Cell Surface; Receptors, Tumor Necrosis Factor; Subcutaneous Fat; Thiazolidinediones; TWEAK Receptor | 2012 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Factors; Flutamide; Hirsutism; Humans; Hyperandrogenism; Hyperinsulinism; Longitudinal Studies; Metformin; Pioglitazone; Thiazolidinediones | 2016 |
20 other study(ies) available for metformin and flutamide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; Diabetes Complications; Dopamine Agonists; Ergolines; Female; Finasteride; Flutamide; Follicle Stimulating Hormone; Gonadotropins; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Mineralocorticoid Receptor Antagonists; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Risk Factors; Spironolactone; Weight Loss | 2004 |
Hirsutism.
Topics: Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Female; Flutamide; Hirsutism; Humans; Hypoglycemic Agents; Metformin | 2006 |
Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women.
Topics: Adolescent; Adult; Androgen Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flutamide; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Metformin | 2006 |
Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Topics: Aging; Androgen Antagonists; Body Weight; Child; Drug Therapy, Combination; Female; Fetal Development; Fetal Weight; Flutamide; Humans; Hyperinsulinism; Hypoglycemic Agents; Infant, Low Birth Weight; Infant, Newborn; Metformin; Polycystic Ovary Syndrome; Puberty, Precocious | 2006 |
Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice.
Topics: Analysis of Variance; Androgen Antagonists; Animals; Body Weight; Diet, Fat-Restricted; Dietary Fats; Fatty Acids, Nonesterified; Female; Flutamide; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Mice; Mice, Inbred C57BL; Receptors, Androgen; Sexual Maturation; Testosterone | 2009 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Humans; Hyperandrogenism; Hyperinsulinism; Menstruation Disturbances; Metformin; Obesity; Pioglitazone; Thiazolidinediones | 2014 |
Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.
Topics: Androgen Antagonists; Androgens; Animals; Estrous Cycle; Female; Fetal Development; Flutamide; Hypoglycemic Agents; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Rosiglitazone; Sexual Maturation; Sheep; Sheep, Domestic; Testosterone; Thiazolidinediones | 2015 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone; Endothelium, Vascular; Female; Flutamide; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Random Allocation; Rats, Wistar; Time Factors; Vasodilation | 2015 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood Glucose; Cardiovascular Diseases; Disease Models, Animal; Estrogen Receptor alpha; Female; Flutamide; Follicular Phase; Hypoglycemic Agents; Insulin; Insulin Resistance; Intestinal Mucosa; Liver; Metabolic Syndrome; Metformin; Mitogen-Activated Protein Kinase 1; Ovarian Follicle; Ovary; Polycystic Ovary Syndrome; Proto-Oncogene Proteins c-akt; Rats; Receptor, Insulin; Risk; RNA, Messenger; Triglycerides | 2019 |
Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model.
Topics: Animals; Body Weight; Clomiphene; Female; Fertility Agents, Female; Flutamide; Humans; Infertility, Female; Metformin; Mice; Oocytes; Ovulation Induction; Polycystic Ovary Syndrome | 2022 |